Ranbaxy announces settlement of possible Imitrex litigation with Glaxosmithkline

21 Jan 2008

1

Ranbaxy Laboratories Ltd has announced the settlement of "all matters relating to possible patent litigation with GlaxoSmithKline relating to Sumatriptan Succinate tablets", the generic version of GlaxoSmithKline's Imitrex tablets.

The terms of the settlement, provide that Ranbaxy may distribute a generic version of Sumatriptan Succinate tablets in the 25mg, 50mg and 100mg strengths in the United
States with an expected launch date in December 2008.

Additional terms of the settlement agreement were not disclosed.

The annual market sales for Sumatriptan Succinate (Imitrex) were $985 million (IMS- MAT: Sept 2007).

 

Business History Videos

History of hovercraft Part 3...

Today I shall talk a bit more about the military plans for ...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of hovercraft Part 2...

In this episode of our history of hovercraft, we shall exam...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Hovercraft Part 1...

If you’ve been a James Bond movie fan, you may recall seein...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Trams in India | ...

The video I am presenting to you is based on a script writt...

By Aniket Gupta | Presenter: Sheetal Gaikwad

view more